What you suggest makes sense to me. Revance has a powerful story to tell with RT002 and the way they tell it commercially will make or break them. What they can and can't do is central to whether it made sense to get an early commercial team in place.
Dr. Jean Carruthers is known as the doctor that discovered that Botox could be used for Dystonia and Gabellar lines. She was a lead investigator in both the Belmont and Sakura studies has been featured in the Revance press releases. I have to believe she will be part of the Revance Commercial strategy in the medical community. There are several videos of her speaking about Botox that I think are must sees for anyone interested in Revance. Here are the links:
Market Data 
Markets 
AI
